TY - JOUR
T1 - Postsurgical surveillance
T2 - How intensive should it be?
AU - Dicato, M.
AU - Cherrier, S.
AU - Van Custsem, E.
AU - Berchem, G.
PY - 2007/2
Y1 - 2007/2
N2 - The best target group for surveillance after curative surgery is the stage III and postcurative stage IV disease group of patients. Most patients who relapse will do so 3 to 5 years after surgery. Newer drugs might delay the relapse period. Overall, only a small number of patients will benefit. There is a need for large, well designed, randomized studies, but these are difficult to do. Additional techniques will have to be validated as they come along. A general recommendation at the present time could be: physician evaluation, carcinoembryonic antigen testing, liver imaging, and colonoscopy. The frequency of these modalities at 3 and 6 months seems reasonable knowing that there is no final survival advantage demonstrated by randomized studies as of yet.
AB - The best target group for surveillance after curative surgery is the stage III and postcurative stage IV disease group of patients. Most patients who relapse will do so 3 to 5 years after surgery. Newer drugs might delay the relapse period. Overall, only a small number of patients will benefit. There is a need for large, well designed, randomized studies, but these are difficult to do. Additional techniques will have to be validated as they come along. A general recommendation at the present time could be: physician evaluation, carcinoembryonic antigen testing, liver imaging, and colonoscopy. The frequency of these modalities at 3 and 6 months seems reasonable knowing that there is no final survival advantage demonstrated by randomized studies as of yet.
UR - http://www.scopus.com/inward/record.url?scp=84873336824&partnerID=8YFLogxK
U2 - 10.1007/s11888-007-0014-6
DO - 10.1007/s11888-007-0014-6
M3 - Review article
AN - SCOPUS:84873336824
SN - 1556-3790
VL - 3
SP - 35
EP - 38
JO - Current Colorectal Cancer Reports
JF - Current Colorectal Cancer Reports
IS - 1
ER -